05:30 AM EDT, 09/02/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Sunday a real-world study showed that Wegovy cut the risk of heart attack, stroke or death by 57%, compared with tirzepatide in patients with obesity and cardiovascular disease.

The study analyzed patient outcomes and found 15 cardiovascular events with Wegovy versus 39 with tirzepatide, the company said.

Across all treated participants, including those with treatment gaps, Wegovy users saw a 29% lower risk of heart attack, stroke, or death compared with tirzepatide, Novo Nordisk ( NVO ) said.

The company also said the average follow-up was 3.8 months for Wegovy patients and 4.3 months for tirzepatide patients in the primary analysis.

Shares of Novo Nordisk ( NVO ) rose 1% in recent premarket activity Tuesday.